Organizations operate with an objective of wealth maximization by creating a sense of assurance that their operations are ethical and beneficial to society. This assurance can be evaluated with the help of the Corporate Social Responsibility (CSR) report. CSR is a plan of action to measure and to find out the contribution in improving the quality of life of society. Quality of life is a widely debated term as it represents the standard of living and status of health. In the present scenario, the phrase “health is wealth” is the real meaning of quality of life. The pharmaceutical industry has a major role to play in improving the health of its people. India is the world’s largest producer of pharmaceutical products which includes medicines and vaccines. Indian pharmaceutical industries provide 60% of the world’s supply which is being used both by the developing and developed countries. Indian industries are quite sensitive to medicine at affordable prices. As a result, they have acquired a reputation as the provider of standard, safe, and efficacious medicines across the globe. This has earned them the reputation of “Pharmacy of the World”. Indian pharma has proactively engaged in developing covid-19 drugs and essentials to protect the life of the people. They have collaborated with global farms to accelerate the process of drugs manufacturing and distribution. Looking at its proactive participation and intent to be ahead in terms of drug availability to tackle the covid-19 pandemic situation, an attempt has been made to study the CSR practices of three important pharmaceutical industries in India. Therefore, the paper attempts to i) assess the CSR disclosure practices followed by pharmaceutical companies with the help of content analysis and checklist; ii) examine the association between firm size/ownership structure with that of the quantity or quality of CSR disclosures by the help of regression analysis.